A specific signature of 19 circulating miRNAs (osteomiRs) has been reported to be associated with fragility fractures due to postmenopausal osteoporosis. However, it is unknown whether osteoporotic fractures or low BMD phenotypes are independently contributing to changes in osteomiR serum levels. The first aim was to characterize the abundance, sensitivity to hemolysis, and correlation of osteomiR serum levels, the second objective to evaluate the diagnostic accuracy of osteomiRs for osteoporosis according to the WHO criteria and on basis of major osteoporotic fracture history. Fifty postmenopausal women with osteoporosis (with or without fragility fracture) and 50 non-osteoporotic women were included in this cross-sectional study. The diagnostic performance of osteomiRs for osteoporosis based on the WHO definition or fracture history was evaluated using multiple logistic regression and receiver-operator curve (AUC) analysis. The osteomiR® signature is composed of four clusters of miRNAs providing good performance for the diagnosis of osteoporosis in postmenopausal women defined by WHO criteria (AUC = 0.830) and based on history of major osteoporotic fractures (AUC = 0.834). The classification performance for the WHO criteria and for fracture risk is driven by miR-375 and miR-203a, respectively. OsteomiRs, a signature of 19 emerging miRNA bone biomarkers, are measurable in human serum samples. They constitute a panel of independent bone and muscle biomarkers, which in combination could serve as diagnostic biomarkers for osteoporosis in postmenopausal women.

据报道，19 种循环 miRNA (osteomiRs) 的特定特征与绝经后骨质疏松症引起的脆性骨折有关。然而，尚不清楚骨质疏松性骨折或低 BMD 表型是否独立地导致了osteomiR 血清水平的变化。第一个目的是表征 osteomiR 血清水平的丰度、对溶血的敏感性和相关性，第二个目的是根据 WHO 标准并根据主要的骨质疏松性骨折病史评估 osteomiRs 对骨质疏松症的诊断准确性。这项横断面研究包括 50 名患有骨质疏松症（有或没有脆性骨折）的绝经后妇女和 50 名非骨质疏松症妇女。使用多元逻辑回归和接受者 - 操作曲线（AUC）分析评估基于WHO定义或骨折史的osteomiRs对骨质疏松症的诊断性能。osteomiR® 特征由四组 miRNA 组成，可根据 WHO 标准 (AUC = 0.830) 和主要骨质疏松性骨折的病史 (AUC = 0.834) 诊断绝经后妇女的骨质疏松症。WHO 标准和骨折风险的分类性能分别由 miR-375 和 miR-203a 驱动。OsteomiRs 是 19 种新兴 miRNA 骨生物标志物的特征，可在人血清样本中进行测量。它们构成了一组独立的骨骼和肌肉生物标志物，它们结合起来可以作为绝经后妇女骨质疏松症的诊断生物标志物。